Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma

被引:0
作者
Daisy V. Alapat
Kenneth B. Ain
David A. Sloan
Kristin G. Monaghan
Rouzan G. Karabakhtsian
机构
[1] University of Kentucky Medical Center,Department of Pathology and Laboratory Medicine
[2] Veterans Affairs Medical Center,Thyroid Cancer Research Laboratory
[3] University of Kentucky Medical Center,Thyroid Oncology Program, Division of Endocrinology and Molecular Medicine, Department of Internal Medicine
[4] University of Kentucky Medical Center,Department of General Surgery
[5] Henry Ford Hospital,Department of Medical Genetics
来源
Endocrine | 2011年 / 39卷
关键词
Medullary thyroid carcinoma; Calcitonin; CEA; Chromogranin A;
D O I
暂无
中图分类号
学科分类号
摘要
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of parafollicular or C-cells of thyroid that comprises 5–10% of all thyroid cancers [1, 2]. The neoplastic cells secrete calcitonin, carcinoembryonic antigen (CEA), and chromogranin A. Typically, increased serum levels of these tumor markers permit them to be used for initial diagnosis and long-term disease status surveillance. This article reports a case of sporadic MTC (pT2N0M0) in a young patient with normal serum tumor markers. A 16-year-old woman presented with MTC without evidence for this to be a familial case due to the absence of germline mutations in the RET proto-oncogene and negative family history. Surprisingly, there were normal preoperative serum levels of calcitonin, CEA, and chromogranin A, despite the immunohistochemistry showing strong and diffuse positive staining for these markers. This disparity between serum levels and tumor expression of calcitonin and CEA in MTC is quite rare. The relevant features of this case are discussed in consideration of the published experiences. This case may represent an unique subgroup of MTC with abnormal secretory capacity that requires reliance upon radiological evaluation for evidence of recurrent or disseminated disease, without the diagnostic benefit of serum tumor markers.
引用
收藏
页码:148 / 152
页数:4
相关论文
共 41 条
[1]  
Al-Rawi M(2006)undefined Ann. R. Coll. Surg. Engl. 88 433-438
[2]  
Vezzosi D(2007)undefined Ann. Endocrinol. (Paris) 68 147-153
[3]  
Schroder S(1988)undefined Cancer 61 806-816
[4]  
Schmid K(1998)undefined Virchows Arch. 433 209-215
[5]  
Morton RP(2007)undefined Curr. Opin. Otolaryngol. Head Neck Surg. 15 89-94
[6]  
Wells SA(1985)undefined Arch. Intern. Med. 145 1248-1252
[7]  
Bockhorn M(2004)undefined Thyroid 14 468-470
[8]  
Diez JJ(2004)undefined Thyroid 14 984-985
[9]  
Dora JM(2008)undefined Thyroid 18 895-899
[10]  
Giovanella L(2008)undefined Int. J. Biol. Markers 23 129-131